{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:19:01Z","timestamp":1790705941342,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.thromres.2020.09.014","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T01:10:41Z","timestamp":1600305041000},"page":"340-348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Risk of post-thrombotic syndrome after deep vein thrombosis treated with rivaroxaban versus vitamin-K antagonists: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"196","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3959-9105","authenticated-orcid":false,"given":"Ruihao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manqiu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junning","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shixiong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Prandoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yikuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2020.09.014_bb0005","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11239-009-0309-3","article-title":"Incidence and cost burden of post-thrombotic syndrome","volume":"28","author":"Ashrani","year":"2009","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.thromres.2020.09.014_bb0010","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000000130","article-title":"The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association","volume":"130","author":"Kahn","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2020.09.014_bb0015","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1538-7836.2009.03294.x","article-title":"Definition of post-thrombotic syndrome of the leg for use in clinical investigations: a recommendation for standardization","volume":"7","author":"Kahn","year":"2009","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2020.09.014_bb0020","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/jth.13909","article-title":"Investigators SOXT. Development of a clinical prediction model for the postthrombotic syndrome in a prospective cohort of patients with proximal deep vein thrombosis","volume":"16","author":"Rabinovich","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2020.09.014_bb0025","article-title":"Risk and protective factors for post-thrombotic syndrome after deep venous thrombosis","author":"Cucuruz","year":"2019","journal-title":"J. Vasc. Surg. Venous Lymphat. Disord."},{"key":"10.1016\/j.thromres.2020.09.014_bb0030","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1055\/s-0035-1544161","article-title":"The impact of residual thrombosis on the long-term outcome of patients with deep venous thrombosis treated with conventional anticoagulation","volume":"41","author":"Prandoni","year":"2015","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2020.09.014_bb0035","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1055\/s-0038-1666859","article-title":"Predicting post-thrombotic syndrome with ultrasonographic follow-up after deep vein thrombosis: a systematic review and meta-analysis","volume":"118","author":"Dronkers","year":"2018","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2020.09.014_bb0040","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.thromres.2017.07.026","article-title":"Epidemiology of the post-thrombotic syndrome","volume":"164","author":"Galanaud","year":"2018","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2020.09.014_bb0045","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1538-7836.2005.01333.x","article-title":"Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome","volume":"3","author":"van Dongen","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2020.09.014_bb0050","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1111\/j.1538-7836.2012.04872.x","article-title":"Risk of post-thrombotic syndrome after subtherapeutic warfarin anticoagulation for a first unprovoked deep vein thrombosis: results from the REVERSE study","volume":"10","author":"Chitsike","year":"2012","journal-title":"J. Thromb. Haemost."},{"issue":"e3","key":"10.1016\/j.thromres.2020.09.014_bb0055","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.amjmed.2008.12.023","article-title":"Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome","volume":"122","author":"Hull","year":"2009","journal-title":"Am. J. Med."},{"key":"10.1016\/j.thromres.2020.09.014_bb0060","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2020.09.014_bb0065","doi-asserted-by":"crossref","first-page":"636","DOI":"10.2174\/1389200218666170518165443","article-title":"Rivaroxaban - metabolism, pharmacologic properties and drug interactions","volume":"18","author":"Kvasnicka","year":"2017","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.thromres.2020.09.014_bb0070","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/rth2.12222","article-title":"Direct oral anticoagulants and warfarin for venous thromboembolism treatment: trends from 2012 to 2017","volume":"3","author":"Lutsey","year":"2019","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2020.09.014_bb0075","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest."},{"key":"10.1016\/j.thromres.2020.09.014_bb0080","doi-asserted-by":"crossref","first-page":"106608","DOI":"10.1016\/j.vph.2019.106608","article-title":"Low prevalence of post-thrombotic syndrome in patients treated with rivaroxaban","volume":"124","author":"Ferreira","year":"2020","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.thromres.2020.09.014_bb0085","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.surg.2019.05.030","article-title":"Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin","volume":"166","author":"de Athayde Soares","year":"2019","journal-title":"Surgery"},{"key":"10.1016\/j.thromres.2020.09.014_bb0090","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.thromres.2018.01.013","article-title":"Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome","volume":"163","author":"Utne","year":"2018","journal-title":"Thromb. Res."},{"issue":"e4","key":"10.1016\/j.thromres.2020.09.014_bb0095","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.amjmed.2018.01.041","article-title":"Rivaroxaban versus warfarin and risk of post-thrombotic syndrome among patients with venous thromboembolism","volume":"131","author":"Sogaard","year":"2018","journal-title":"Am. J. Med."},{"key":"10.1016\/j.thromres.2020.09.014_bb0100","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1177\/1076029618758955","article-title":"Postthrombotic syndrome in patients treated with rivaroxaban or warfarin for venous thromboembolism","volume":"24","author":"Coleman","year":"2018","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2020.09.014_bb0105","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"Bmj"},{"key":"10.1016\/j.thromres.2020.09.014_bb0115","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.thromres.2018.10.027","article-title":"Rivaroxaban or vitamin-K antagonists following early endovascular thrombus removal and stent placement for acute iliofemoral deep vein thrombosis","volume":"172","author":"Sebastian","year":"2018","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2020.09.014_bb0120","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.thromres.2017.05.029","article-title":"Rivaroxaban versus warfarin in the prevention of post-thrombotic syndrome","volume":"157","author":"Jeraj","year":"2017","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2020.09.014_bb0125","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1160\/TH16-01-0041","article-title":"Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin\/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis","volume":"116","author":"Cheung","year":"2016","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2020.09.014_bb0130","article-title":"The risk of post-thrombotic syndrome in patients with proximal deep vein thrombosis treated with the direct oral anticoagulants","author":"Prandoni","year":"2019","journal-title":"Intern. Emerg. Med."},{"key":"10.1016\/j.thromres.2020.09.014_bb0135","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1160\/th15-04-0318","article-title":"Development and validation of a tool for patient reporting of symptoms and signs of the post-thrombotic syndrome","volume":"115","author":"Utne","year":"2016","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2020.09.014_bb0140","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S0140-6736(13)61902-9","article-title":"Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial","volume":"383","author":"Kahn","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2020.09.014_bb0145","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.thromres.2017.10.022","article-title":"Diagnostic scales for the post-thrombotic syndrome","volume":"164","author":"Wik","year":"2018","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2020.09.014_bb0150","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.106.668020","article-title":"Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study","volume":"116","author":"Agnelli","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2020.09.014_bb0155","doi-asserted-by":"crossref","first-page":"17","DOI":"10.23736\/S0392-9590.18.04031-2","article-title":"Treatment of deep vein thrombosis with rivaroxaban and its potential to prevent the post-thrombotic syndrome","volume":"38","author":"Antignani","year":"2019","journal-title":"Int. Angiol."},{"key":"10.1016\/j.thromres.2020.09.014_bb0160","doi-asserted-by":"crossref","first-page":"e20180111","DOI":"10.1590\/1677-5449.180111","article-title":"Analysis of recanalization of deep venous thrombosis: a comparative study of patients treated with warfarin vs. rivaroxaban","volume":"18","author":"Piati","year":"2019","journal-title":"J. Vasc. Bras."},{"key":"10.1016\/j.thromres.2020.09.014_bb0165","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00228-014-1693-y","article-title":"Potential use of NOACs in developing countries: pros and cons","volume":"70","author":"Bista","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.thromres.2020.09.014_bb0170","first-page":"551","article-title":"New oral anticoagulants: need and challenges in a developing country","volume":"26","author":"Khan","year":"2016","journal-title":"J. Coll. Physicians Surg. Pak."},{"key":"10.1016\/j.thromres.2020.09.014_bb0175","first-page":"1","article-title":"Medical costs of treating venous stasis ulcers: evidence from a retrospective cohort study","volume":"4","author":"Olin","year":"1999","journal-title":"Vasc. Med."},{"key":"10.1016\/j.thromres.2020.09.014_bb0180","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.thromres.2005.12.005","article-title":"A cost analysis of the treatment of patients with post-thrombotic syndrome in Brazil","volume":"118","author":"Ramacciotti","year":"2006","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2020.09.014_bb0185","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.2146\/ajhp060388","article-title":"Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome","volume":"63","author":"MacDougall","year":"2006","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.thromres.2020.09.014_bb0190","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0190-9622(94)70134-2","article-title":"A study of the impact of leg ulcers on quality of life: financial, social, and psychologic implications","volume":"31","author":"Phillips","year":"1994","journal-title":"J. Am. Acad. Dermatol."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384820305181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384820305181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:45:37Z","timestamp":1758735937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384820305181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":37,"alternative-id":["S0049384820305181"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2020.09.014","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of post-thrombotic syndrome after deep vein thrombosis treated with rivaroxaban versus vitamin-K antagonists: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2020.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}